Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03272711 · ClinicalTrials.gov registry record · Phase 4
Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training
A Phase 4 study of Age-related Cognitive Decline, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 129
- Enrollment target
- 1
- Study location
NCT03272711: Completed Phase 4 study of Age-related Cognitive Decline, sponsored by Washington University School of Medicine.
NCT03272711 is a Phase 4 study of Age-related Cognitive Decline that has completed, run by Washington University School of Medicine. The registered enrollment target is 129 participants, below the 1,120-participant average among 10 other Age-related Cognitive Decline trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03272711, a Phase 4 study of Age-related Cognitive Decline, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 129 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to examine the potential benefits of vortioxetine in combination with at-home computerized cognitive training program to improve cognition, such as memory, attention, and concentration. This study will compare the effectiveness of vortioxetine plus cognitive training versus placebo plus cognitive training.
Primary Outcome
Total fluid cognitive score from the NIH Toolbox as well as the speed of cognitive improvement The study utilized five cognitive tests from the NIH Toolbox Cognitive Battery that measured "fluid" cognition-the capacity for new learning and information processing. A higher score indicates indicates better performance on these tests. A total fluid cognitive score at or near 100 indicates ability that is average compared with others nationally. Scores around 115 suggest above-average fluid cognitiv
Conditions Studied
Interventions
- DRUG Vortioxetine 10 mg
- BEHAVIORAL Cognitive training program
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2016-08-31 |
| Est. Completion | 2019-01-24 |
| Phase | Phase 4 |
What the finished NCT03272711 record still lists
NCT03272711 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, below the 1,120-participant average among 10 other Age-related Cognitive Decline trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Age-related Cognitive Decline appearing as the primary indexed condition, and to 2 interventions - of which Vortioxetine 10 mg is the first listed.
NCT03272711 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT03272711 about?
NCT03272711 is a clinical study titled "Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training". The purpose of this research study is to examine the potential benefits of vortioxetine in combination with at-home computerized cognitive training program to improve cognition, such as memory, attention, and concentration. This study will compare the effectiveness of vortioxetine plus cognitive tra...
What is the current status of trial NCT03272711?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 129 participants. The study started on 2016-08-31. Estimated completion is 2019-01-24.
What conditions does trial NCT03272711 study?
This clinical trial studies the following conditions: Age-related Cognitive Decline.
What interventions are being tested in trial NCT03272711?
The interventions under investigation include: Vortioxetine 10 mg (DRUG), Cognitive training program (BEHAVIORAL).
Who is sponsoring clinical trial NCT03272711?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03272711 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Cognitive Decline
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03272711's enrollment target sits among peer trials
129 6th of 10 higher than 5 of 10 other Age-related Cognitive Decline trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Age-related Cognitive Decline trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Older Breast Cancer Patients: Risk for Cognitive Decline
RECRUITING
-
Acute Effects of THC in Older Adult
RECRUITING · Phase 1
-
Feasibility and Adherence to a Technology-assisted Home-based Strength Training Program in Adults With Type 2 Diabetes Mellitus and Mild Cognitive Impairment
RECRUITING · NA
-
The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia
RECRUITING · NA
-
Preventing Alzheimer's With Cognitive Training
RECRUITING · Phase 3
-
Cardiac-Control Affecting Learning Through Mindfulness (CALM)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI